Limits...
Changes in Peak Flow value during immunotherapy administration.

Saporta D - J Environ Public Health (2012)

Bottom Line: Not only the upper respiratory tract but the whole body is involved.A very significant finding was that most allergy sufferers may have lower airway inflammation.A better diagnosis of lower airway inflammation could be substantial in the management of these patients.

View Article: PubMed Central - PubMed

Affiliation: Associates in ENT & Allergy, PA 470 North Aveue, Elizabeth, NJ 07208, USA. saporta.allergy@gmail.com

ABSTRACT
Nasal allergies are prevalent affecting a large percentage of the population. Not only the upper respiratory tract but the whole body is involved. Allergies produce morbidity (and even occasional mortality) as they can lead to asthma development, and increased number of accidents. Immunotherapy results can be evaluated by following symptom scores, medication use, and objective measurements. Using a Peak Flow Meter (PFM) to evaluate immunotherapy results, it became evident that patients with and without asthma exhibited an improvement in the Peak Flow (PF) value, suggesting that lower airway involvement in allergic patients could be more prevalent than assumed. A consecutive chart review was performed including patients of any age with nasal allergies (with or without asthma) treated with immunotherapy for at least 6 months that had at least 2 complete evaluations. When immunotherapy was successful, most patients exhibited an increase in the PF value regardless of asthma status. A very significant finding was that most allergy sufferers may have lower airway inflammation. The use of the PF value to assess immunotherapy results and the potential failure to diagnose asthma in allergy sufferers are discussed. A better diagnosis of lower airway inflammation could be substantial in the management of these patients.

Show MeSH

Related in: MedlinePlus

Total sample and subgroups. Total sample: 60 subjects, 13 report asthma, 47 do not. Total sample subdivided: 13 report asthma, Remainder 47: 30 have cough and other asthma symptoms, 11 have cough only, and 6 have no cough or other asthma symptoms. Cough: 53/60 subjects had cough.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3306949&req=5

fig2: Total sample and subgroups. Total sample: 60 subjects, 13 report asthma, 47 do not. Total sample subdivided: 13 report asthma, Remainder 47: 30 have cough and other asthma symptoms, 11 have cough only, and 6 have no cough or other asthma symptoms. Cough: 53/60 subjects had cough.

Mentions: A diagnosis of asthma was self-reported by 13 subjects (21% of the total sample), and only 1 of these subjects did not report cough as one of the symptoms. The remaining 47 subjects denied having asthma, although 30 reported asthma symptoms (30/47 = 63.8%) (see Figure 2).


Changes in Peak Flow value during immunotherapy administration.

Saporta D - J Environ Public Health (2012)

Total sample and subgroups. Total sample: 60 subjects, 13 report asthma, 47 do not. Total sample subdivided: 13 report asthma, Remainder 47: 30 have cough and other asthma symptoms, 11 have cough only, and 6 have no cough or other asthma symptoms. Cough: 53/60 subjects had cough.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3306949&req=5

fig2: Total sample and subgroups. Total sample: 60 subjects, 13 report asthma, 47 do not. Total sample subdivided: 13 report asthma, Remainder 47: 30 have cough and other asthma symptoms, 11 have cough only, and 6 have no cough or other asthma symptoms. Cough: 53/60 subjects had cough.
Mentions: A diagnosis of asthma was self-reported by 13 subjects (21% of the total sample), and only 1 of these subjects did not report cough as one of the symptoms. The remaining 47 subjects denied having asthma, although 30 reported asthma symptoms (30/47 = 63.8%) (see Figure 2).

Bottom Line: Not only the upper respiratory tract but the whole body is involved.A very significant finding was that most allergy sufferers may have lower airway inflammation.A better diagnosis of lower airway inflammation could be substantial in the management of these patients.

View Article: PubMed Central - PubMed

Affiliation: Associates in ENT & Allergy, PA 470 North Aveue, Elizabeth, NJ 07208, USA. saporta.allergy@gmail.com

ABSTRACT
Nasal allergies are prevalent affecting a large percentage of the population. Not only the upper respiratory tract but the whole body is involved. Allergies produce morbidity (and even occasional mortality) as they can lead to asthma development, and increased number of accidents. Immunotherapy results can be evaluated by following symptom scores, medication use, and objective measurements. Using a Peak Flow Meter (PFM) to evaluate immunotherapy results, it became evident that patients with and without asthma exhibited an improvement in the Peak Flow (PF) value, suggesting that lower airway involvement in allergic patients could be more prevalent than assumed. A consecutive chart review was performed including patients of any age with nasal allergies (with or without asthma) treated with immunotherapy for at least 6 months that had at least 2 complete evaluations. When immunotherapy was successful, most patients exhibited an increase in the PF value regardless of asthma status. A very significant finding was that most allergy sufferers may have lower airway inflammation. The use of the PF value to assess immunotherapy results and the potential failure to diagnose asthma in allergy sufferers are discussed. A better diagnosis of lower airway inflammation could be substantial in the management of these patients.

Show MeSH
Related in: MedlinePlus